Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples
Posted by Corey Marcath on
Human Serum from Innovative Research was used in the following study:
Thomas L. Rudge Jr. ,Karen A. Sankovich,Nancy A. Niemuth,Michael S. Anderson,Christopher S. Badorrek,Nick D. Skomrock,Chris M. Cirimotich,Carol L. Sabourin
Plos One
April 18, 2019
“The need for an efficacious vaccine against highly pathogenic filoviruses was reinforced by the recent and devastating 2014–2016 outbreak of Ebola virus (EBOV) disease in Guinea, Sierra Leone, and Liberia that resulted in more than 10,000 casualties. …The negative control (NC) serum (0 ELISA units/mL, Lot Number BMI530) was generated by pooling equivalent volumes of 23 individual naïve human serum samples purchased from Innovative Research (Novi, MI)…”
Related products available from Innovative Research also include: